Plexus Corp. (PLXS) Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 28, 2025 (Fiscal Q3 2025). Plexus Corp. is a global contract manufacturer providing design, manufacturing, and service solutions for the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The company operates across three geographic segments: Americas (AMER), Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $1,018.3 million | $960.8 million | $2,974.6 million | $2,910.3 million |
| Gross Profit | $103.3 million | $94.4 million | $301.7 million | $270.6 million |
| Gross Margin | 10.1% | 9.8% | 10.1% | 9.3% |
| Operating Income | $53.6 million | $39.2 million | $149.3 million | $113.9 million |
| Operating Margin | 5.3% | 4.1% | 5.0% | 3.9% |
| Net Income | $45.1 million | $25.1 million | $121.5 million | $70.6 million |
| Diluted EPS | $1.64 | $0.91 | $4.39 | $2.53 |
| Cash & Equivalents | $237.6 million (as of June 28, 2025) | |||
| Total Debt | $142.9 million (as of June 28, 2025) | |||
| Free Cash Flow (YTD) | $56.8 million | $147.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.0% in Q3 and 2.2% YTD compared to the prior year. Growth was driven primarily by the APAC segment (+13.9% Q3, +12.0% YTD) and the Healthcare/Life Sciences sector (+10.6% Q3, +5.8% YTD).
- Profitability Expansion: Operating income surged 36.7% in Q3 and 31.1% YTD. This was driven by improved gross margins (up 30 bps Q3, 80 bps YTD) due to operational efficiencies and a significant reduction in restructuring charges.
- Restructuring Charges: Q3 2025 had no restructuring charges, compared to $9.2 million in Q3 2024. YTD 2025 charges were $4.7 million versus $20.3 million in YTD 2024.
- Segment Performance:
- APAC: Strong growth in sales and operating income (+11.4% Q3).
- AMER: Sales up 1.7% Q3; operating income up 19.6% Q3.
- EMEA: Sales declined 14.3% Q3 and 21.7% YTD due to decreased end-market demand.
- Debt Reduction: The company repaid $100.0 million in 4.05% Senior Notes upon maturity on June 15, 2025. Total debt obligations decreased from $247.3 million (Sept 2024) to $142.9 million (June 2025).
Guidance, Outlook, and Risks
- Tax Outlook: The annual effective tax rate for fiscal 2025 is expected to be approximately 10.0% to 12.0%. Management is currently evaluating the impact of the "One Big Beautiful Bill Act" enacted on July 4, 2025.
- Capital Expenditures: Estimated at $80.0 million to $100.0 million for fiscal 2025 to support new program ramps.
- Share Repurchases: The company completed its $50.0 million "2025 Program" and initiated a new $100.0 million "2026 Program" in May 2025. YTD 2025 repurchases totaled $43.4 million.
- Risks: Key risks include global economic conditions, supply chain constraints, component shortages, foreign currency fluctuations, and customer demand volatility. The company notes that 92% of cash is held outside the U.S.
Investor Verification Checklist
- EMEA Demand: Verify the sustainability of the 21.7% YTD sales decline in the EMEA region and its impact on future capacity utilization.
- Working Capital Efficiency: Review the 14-day improvement in the annualized cash cycle (69 days vs. 83 days prior year) to ensure it reflects operational efficiency rather than delayed supplier payments.
- Tax Rate Volatility: Monitor the impact of the new "One Big Beautiful Bill Act" on the projected 10-12% effective tax rate.
- Debt Maturity Profile: Confirm the remaining debt structure post-$100M note repayment and the utilization of the revolving credit facility.
- Inventory Levels: Assess the $1.28 billion inventory balance against the 128 days of inventory on hand to evaluate obsolescence risks in the current economic climate.